Hygiene products firm Essity eyes vaccine effect after Q1 profit dives


Q1 EBIT 3.5 bln SEK vs consensus 3.6 bln SEK

Organic sales down 10%

Company says restrictions, lockdowns hit sales

Adds company comment, details on results

STOCKHOLM, April 23 (Reuters) - Hygiene products maker Essity ESSITYb.ST reported a slightly bigger-than-expected drop in first-quarter operating profit on Friday, but said it expected COVID-19 vaccination programmes to boost demand for many of its products.

Operating earnings for the period fell 32% to 3.48 billion crowns ($413.3 million) on an organic sales drop of 10%, following restrictions and lockdowns to slow the COVID-19 pandemic. Analysts had expected a profit of 3.64 billion crowns, according to Refinitiv IBES data.

"Improved market conditions resulting from the ongoing vaccination programmes are expected to result in increased demand for several of Essity's product categories," the Swedish company said.

Significantly higher sales in China in the first quarter, and an increase in demand in North America at its professional hygiene division pointed to that, according to Essity.

The company said it expects a previously announced restructuring programme to "contribute to Essity's total annual cost savings of 500 million to 1 billion crowns through the optimization of the production structure, productivity improvements and raw material and energy savings".

($1 = 8.4211 Swedish crowns)

(Reporting by Anna Ringstrom; Editing by Helena Soderpalm and Shounak Dasgupta)

((anna.ringstrom@thomsonreuters.com; +46 8 502 423 74; Reuters Messaging: anna.ringstrom.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.